Future studies are warranted to gain detailed mechanistic insight into these biological activities – in adipocytes, but also in other vaspin target tissues such as liver, skin or the vasculature– and these may clarify, if synthetic vaspin-derived peptides may have potential as therapeutic agents for the treatment of metabolic diseases. The gene discussed is SERPINA12; the disease is metabolic disease.